1.74
+0.01(+0.58%)
Currency In USD
| Previous Close | 1.73 |
| Open | 1.76 |
| Day High | 1.8 |
| Day Low | 1.65 |
| 52-Week High | 8.27 |
| 52-Week Low | 1.12 |
| Volume | 797,762 |
| Average Volume | 1.44M |
| Market Cap | 228.22M |
| PE | -1.05 |
| EPS | -1.65 |
| Moving Average 50 Days | 1.89 |
| Moving Average 200 Days | 3.26 |
| Change | 0.01 |
If you invested $1000 in Prime Medicine, Inc. (PRME) since IPO date, it would be worth $113.21 as of May 02, 2025 at a share price of $1.74. Whereas If you bought $1000 worth of Prime Medicine, Inc. (PRME) shares 2 years ago, it would be worth $126.55 as of May 02, 2025 at a share price of $1.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire Inc.
Mar 18, 2025 11:00 AM GMT
-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High levels of editing at the target site in preclinic
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2025 1:00 PM GMT
CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.
Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D